As human inherited erythromelalgia (IEM) and paroxysmal extreme pain disorder (PEPD) are caused by mutations that increase Nav1.7 opening [11], we attempted to mimic the effects of such mutations pharmacologically with the lipophilic small molecules veratradine and grayanotoxin III. The gene discussed is SCN9A; the disease is paroxysmal extreme pain disorder.